Jefferies Recommends AbbVie (ABBV) as Quality Stock Amid AI Concerns
Published on Β· Source: cnbc.com
AI Summary
Summarized by AI from the source belowJefferies has recommended quality, low-stress stocks amid increasing market volatility related to artificial intelligence investments. They specifically highlight AbbVie (ABBV), predicting nearly 28% compound annual earnings growth for 2026-2027 and a free cash flow yield of 5.2%. AbbVie's first-quarter net revenues reached $15 billion, led by its immunology portfolio of $7.3 billion. The stock has appreciated 25% over the last three months and 37% in the past year, offering a yield of 2.7%. This is important for investors as it suggests stable investment options amidst market fluctuations.
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
About AbbVie Inc. (ABBV)
AbbVie is a research-based pharmaceutical company with a portfolio spanning immunology, oncology, and neuroscience.
The Health Care sector covers pharmaceutical, biotech, device and managed-care companies.
Earlier ABBV news
- AbbVie (ABBV) Hits New 52-Week High; Stock Up 40% Yearly
- AbbVie (ABBV) Acquires Apogee for $10.9 Billion Eczema Drug
- AbbVie (ABBV) Acquires Apogee for $10.9 Billion in Immunology Deal
- Dividend Portfolio Return: $43,770 Annual Income and $7,515 Tax Impact
- Johnson & Johnson (JNJ) Q1 2026 Revenue Hits $24.06 Billion
Get the weekly market brief
One email every Monday: what moved, why, and what to watch. Free, unsubscribe anytime.
Get stories like this as they break
Our Telegram channel posts every market story the moment it is published. Free, and you can mute or leave anytime.
